In 2015 this bioproduct was patented and licensed by ANVISA (National Health Surveillance Agency) and CONEP (National Council of Ethics in Research) for use in clinical research in a trial phase I / II. Based on that researchers from Cevap - Center for the Study of Venoms and Venomous Animals of UNESP - proposed about 20 years ago the prospect of a new heterologous sealant from a Spase isolated from Crotalus durissus terrificus snake venom and fibrinogen purified from large animals (buffaloes). It can polymerize acquiring seala nt and adhesive capacities by forming a stable network. Snake venom serine proteases (SPases) have type-thrombin enzymatic activity (thrombin like-enzyme) acting on the hemostatic system converting fibrinogen to fibrin.
0 Comments
Leave a Reply. |